Match!
Masafumi Fukagawa
Tokai University
EndocrinologySecondary hyperparathyroidismParathyroid hormoneDiabetes mellitusMedicine
584Publications
51H-index
10.6kCitations
What is this?
Publications 585
Newest
Source
#1Naoto Hamano (Tokai University)H-Index: 2
#2Yuichi EndoH-Index: 2
Last. Masafumi Fukagawa (Tokai University)H-Index: 51
view all 4 authors...
INTRODUCTION The calcium-sensing receptor is an important treatment target for secondary hyperparathyroidism (SHPT) in patients undergoing dialysis. In addition to vitamin D receptor activator, cinacalcet has recently been widely used for SHPT management, and the significant suppression of parathyroid hormone (PTH) with better control of serum calcium and phosphorus has been reported. However, low adherence and insufficient dose escalation mainly due to frequent gastrointestinal adverse events, ...
Source
#1Yuichiro Kondo (Tokai University)H-Index: 1
#2Hirotaka Komaba (Tokai University)H-Index: 26
Last. Masafumi Fukagawa (Tokai University)H-Index: 51
view all 3 authors...
INTRODUCTION Among the family of fibroblast growth factors (FGFs), FGF19, FGF21, and FGF23 act as circulating hormones and are called endocrine FGFs. FGF19 and FGF21 regulate bile acid and energy homeostasis, respectively, whereas FGF23 regulates vitamin D and phosphate homeostasis. Accumulating evidence suggests that FGF23 plays a critical role in disturbed mineral metabolisms, left ventricular hypertrophy, immunosuppression, inflammation, among others in patients with chronic kidney disease (C...
Source
#1Tadao Akizawa (Showa University)H-Index: 45
#2Hironori KandaH-Index: 1
Last. Masafumi Fukagawa (Tokai University)H-Index: 51
view all 5 authors...
Source
#2Kazuaki IkejiriH-Index: 1
Last. Masafumi Fukagawa (Tokai University)H-Index: 51
view all 5 authors...
: Patients with chronic kidney disease often develop secondary hyperparathyroidism (SHPT), marked by high levels of circulating parathyroid hormone (PTH) and increased risk of morbidity and mortality. Patients with SHPT are treated with a therapeutic combination that commonly includes calcimimetics, which have recently become popular in clinical settings, and other agents such as vitamin D preparations. Calcimimetics are a drug class that reduces PTH levels by targeting the calcium-sensing recep...
2 CitationsSource
#1Suguru Yamamoto (Niigata University)H-Index: 18
#2Brian BieberH-Index: 20
Last. Masafumi Fukagawa (Tokai University)H-Index: 51
view all 10 authors...
Source
#1Mario Cozzolino (University of Milan)H-Index: 35
view all 9 authors...
INTRODUCTION: This analysis explored laboratory mineral and bone disorder parameters and management of secondary hyperparathyroidism in patients undergoing hemodialysis in Belgium, Canada, China, France, Germany, Italy, Japan, Russia, Saudi Arabia, Spain, Sweden, the UK, and the USA. METHODS: Analyses used demographic, medication, and laboratory data collected in the prospective Dialysis Outcomes and Practice Patterns Study (2012-2015). The analysis included 20,612 patients in 543 facilities. De...
Source
Purpose Evocalcet is a novel oral calcimimetic drug that has demonstrated similar efficacy to cinacalcet in regulating serum parathyroid hormone (PTH), calcium, and phosphate levels, with fewer upper gastrointestinal tract-related adverse drug reactions (ADRs) in patients with secondary hyperparathyroidism undergoing hemodialysis in Japan. We investigated the efficacy and safety of once-daily oral evocalcet under different dialysate calcium concentrations. Patients and Methods A post hoc analysi...
Source
#1Genta KanaiH-Index: 10
#2Takatoshi KakutaH-Index: 21
Last. Masafumi FukagawaH-Index: 51
view all 4 authors...
Source
#1Masaaki MiyauchiH-Index: 10
#2Masao Toyoda (Tokai University)H-Index: 19
Last. Masafumi Fukagawa (Tokai University)H-Index: 51
view all 9 authors...
: We describe here a case of nivolumab-induced type 1 diabetes, which developed within 9 days of treatment. The case highlights the importance of frequent monitoring of glucose after initiation of nivolumab treatment.
1 CitationsSource
12345678910